To report a case of recurrent endometrioid adenocarcinoma treated with everolimus based on the identification of an NF1 mutation.
Key Findings:
The patient had a loss-of-function mutation in the NF1 gene.
Everolimus led to complete remission of recurrent endometrioid adenocarcinoma.
Treatment was associated with severe dyslipidemia, leading to discontinuation.
Interpretation:
This case illustrates the potential of mutation-driven therapeutic decisions in endometrioid adenocarcinoma, emphasizing the role of comprehensive molecular diagnostics.
Limitations:
This is a single case report, limiting generalizability.
Long-term effects of everolimus and its toxicity profile require further investigation.
Conclusion:
This case highlights the treatment of everolimus in NF1-deficient recurrent endometrial cancer.
